TuHURA Biosciences and Kineta, Inc. - Clinical Trial Updates, Aug 19, 2024
TuHURA Biosciences and Kineta, Inc. are collaborating on the VISTA-101 Phase 1/2 clinical trial, where Kineta has resumed patient enrollment during TuHURA's due diligence period for a potential acquisition of Kineta's KVA12123 VISTA blocking antibody. KVA12123 has shown promising results, including partial response and stable disease in combination with Merck's KEYTRUDA® and a favorable safety profile with no dose-limiting toxicities. TuHURA views KVA12123 as a potential addition to their pipeline, with the completion of Phase 1 enrollment anticipated by the end of 2024.
MOMA Therapeutics - Clinical Trial Updates, Aug 19, 2024
MOMA Therapeutics has dosed the first patient in a Phase 1 clinical trial for MOMA-313, an oral polymerase theta helicase inhibitor being developed in combination with a PARP inhibitor for treating solid tumors with specific DNA repair gene alterations. Additionally, MOMA announced the selection of MOMA-341, a Werner helicase inhibitor for cancers with microsatellite instability, as their second lead program, with an IND filing expected in early 2025. CEO Asit Parikh highlighted the rapid clinical advancement of these candidates as a testament to the team's dedication and MOMA's innovative approach to cancer treatment.
Full Article: MOMA Therapeutics Announces Initiation of Phase 1 Clinical Trial for MOMA-313, a Novel Polymerase Theta Helicase Inhibitor
CARsgen Therapeutics - Clinical Trial Updates, Aug 19, 2024
CARsgen Therapeutics has completed enrollment for its pivotal Phase II clinical trial in China for satricabtagene autoleucel ("satri-cel"), an autologous CAR-T therapy targeting Claudin18.2 in advanced gastric and gastroesophageal junction cancers (GC/GEJ). This open-label, multicenter trial evaluates satri-cel in patients who have failed at least two prior therapies. Satri-cel has shown promising efficacy and safety in earlier trials, with a 54.9% overall response rate and a 96.1% disease control rate. CARsgen plans to submit a New Drug Application in China, aiming to bring this innovative therapy to patients with limited treatment options.
Aadi Bioscience - Company Downsizing, Aug 21, 2024
Aadi Bioscience is halting its Phase 2 PRECISION1 trial for Fyarro, an mTOR inhibitor, after an independent committee deemed the study unlikely to meet its efficacy goals for treating solid tumors with TSC1/TSC2 inactivating mutations. This setback has led the biotech to lay off 80% of its R&D workforce, though it will continue dosing patients in two other ongoing Phase 2 trials. The company expects these changes to extend its cash runway into the second half of 2026.
Full Article: Aadi Lays Off 80% of R&D Workforce as Fyarro Heads for Phase 2 Fail
PhotonPharma - Seed Funding, Aug 22, 2024
PhotonPharma, a biopharmaceutical company based in Fort Collins, Colorado, has successfully closed a $2.5 million seed financing round to support the Phase I clinical trial of Innocell, a novel therapy for advanced ovarian cancer. With FDA clearance received in February 2024, the trial is set to begin enrolling patients in Q4 2024. PhotonPharma's leadership, including Chairman Dr. Terry Opgenorth and CEO Dr. Alan Rudolph, views this funding as a pivotal milestone, and the company will present its progress at the upcoming Rocky Mountain Life Sciences Investor and Partnering Conference in September.
Full Article: PhotonPharma Secures $2.5 Million in Seed Funding to Advance Clinical Trial for Ovarian Cancer Treatment
iOmx Therapeutics - Clinical Trial Updates, Aug 22, 2024
iOmx Therapeutics has successfully completed the dose escalation phase of its Phase Ia/Ib trial for OMX-0407, a first-in-class SIK inhibitor, in patients with advanced solid tumors. The trial demonstrated that OMX-0407 was safe and well-tolerated, with evidence of anti-cancer activity, including a complete response in a patient resistant to multiple prior treatments. The company is now entering the expansion phase to evaluate the drug in kidney cancer and angiosarcoma, aiming to generate efficacy data and report proof-of-concept results by early 2026.
Full Article: iOmx Therapeutics Initiates Phase Ib with OMX-0407
Cumulus Oncology and leadXpro - Milestones & Achievements, Aug 22, 2024
Cumulus Oncology and leadXpro (LXP) have achieved milestones in their GPR68 drug discovery project, identifying potent small molecules and solving high-resolution protein structures. Cumulus has licensed the compounds for further development and will advance the program through its Swiss-based company, GIO Therapeutics. LXP will share in future commercialization revenues as the project progresses.
Full Article: Cumulus Oncology and leadXpro Achieve Critical Milestone in GPR68 Drug Discovery Project
BioNTech - Clinical Trial Updates, Aug 24, 2024
A lung cancer patient at University College London Hospitals (UCLH) is the first in the UK to receive a novel mRNA-based cancer vaccine from BioNTech, BNT116, designed to prime the immune system to target non-small cell lung cancer (NSCLC) cells. The trial, supported by the NIHR and part of the UK Vaccine Innovation Pathway, aims to evaluate the vaccine's safety, effectiveness, and potential to enhance existing treatments. The study will enroll around 130 participants across seven countries, with six UK sites involved.
Full Article: BioNTech Begins Trial of Novel mRNA-Based Cancer Vaccine for NSCLC
